Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
Fuster O, Barragán E, Bolufer P, Such E, Valencia A, Ibáñez M, Dolz S, de Juan I, Jiménez A, Gómez MT, Buño I, Martínez J, Cervera J, Montesinos P, Moscardó F, Sanz MÁ. Fuster O, et al. Among authors: moscardo f. Ann Hematol. 2012 Jan;91(1):1-7. doi: 10.1007/s00277-011-1234-z. Epub 2011 May 3. Ann Hematol. 2012. PMID: 21538063
Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients.
Luna I, Such E, Cervera J, Barragán E, Jiménez-Velasco A, Dolz S, Ibáñez M, Gómez-Seguí I, López-Pavía M, Llop M, Fuster Ó, Oltra S, Moscardó F, Martínez-Cuadrón D, Senent ML, Gascón A, Montesinos P, Martín G, Bolufer P, Sanz MA. Luna I, et al. Among authors: moscardo f. Ann Hematol. 2012 Dec;91(12):1845-53. doi: 10.1007/s00277-012-1596-x. Epub 2012 Oct 16. Ann Hematol. 2012. PMID: 23070125
Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
Ibáñez M, Such E, Cervera J, Luna I, Gómez-Seguí I, López-Pavía M, Dolz S, Barragán E, Fuster O, Llop M, Rodríguez-Veiga R, Avaria A, Oltra S, Senent ML, Moscardó F, Montesinos P, Martínez-Cuadrón D, Martín G, Sanz MA. Ibáñez M, et al. Among authors: moscardo f. J Mol Diagn. 2012 Nov;14(6):594-601. doi: 10.1016/j.jmoldx.2012.06.006. Epub 2012 Aug 25. J Mol Diagn. 2012. PMID: 22929312 Free article.
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
Martínez-Cuadrón D, Montesinos P, Oriol A, Salamero O, Vidriales B, Bergua J, Herrera P, Vives S, Sanz J, Carpio C, Rodríguez-Veiga R, Moscardó F, Sanz MA. Martínez-Cuadrón D, et al. Among authors: moscardo f. Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1. Ann Hematol. 2014. PMID: 24081577 Clinical Trial.
WT1 isoform expression pattern in acute myeloid leukemia.
Luna I, Such E, Cervera J, Barragán E, Ibañez M, Gómez-Seguí I, López-Pavía M, Llop M, Fuster O, Dolz S, Oltra S, Alonso C, Vera B, Lorenzo I, Martínez-Cuadrón D, Montesinos P, Senent ML, Moscardó F, Bolufer P, Sanz MA. Luna I, et al. Among authors: moscardo f. Leuk Res. 2013 Dec;37(12):1744-9. doi: 10.1016/j.leukres.2013.10.009. Epub 2013 Oct 22. Leuk Res. 2013. PMID: 24211094
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Among authors: moscardo f. Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Ann Hematol. 2018. PMID: 29392425 Clinical Trial.
73 results